Seegene and Eidia Collaborate
News Jul 09, 2013
"Our partnership with Eidia opens a significant sales channel for our novel diagnostic tests in Japan. We look forward to working with Eidia to improve patient healthcare with highly sensitive and specific multiplexed MoDx tests," said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene. "This deal with Eidia further supports Seegene's leadership in multiplexed molecular technologies and enhances Seegene's strategic market presence in Asia."
Under the terms of the agreement, Seegene will supply a wide range of TOCE™ technology-based multiplexed molecular diagnostic tests, and Eidia will exclusively market and distribute them in Japan. In addition, Eidia will be responsible for obtaining regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.
Enhancing Seegene's market presence in Japan is a key part of Seegene's long-term growth strategy. Partnering with Eidia, an in vitro diagnostic market leader in Japan, will accelerate the adoption of innovative MoDx in that market.
Japan is the third largest diagnostics market in the $52 billion global diagnostics industry, behind North America and Europe.
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
Multi-tissue, Multi-individual Data Used to Identify Mechanisms of Gene RegulationNews
Developing a mechanistic model for how healthy bodies function and how certain diseases merge may now be possible.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018